Nektar Therapeutics | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
Agios Pharmaceuticals USD 7.64M 1.83M 2025-03
ALKERMES USD 257.31M 110.81M 2025-03
Amgen USD 5.54B 430M 2025-03
Baxter International USD 1.02B 19M 2024-12
Biogen USD 1.87B 44.1M 2024-12
Bristol-Myers Squibb USD 8.18B 947M 2025-03
Cipla INR 45.41B 4.9B 2025-03
Dr.Reddys Laboratories INR 56.78B 7.73B 2025-03
Eisai JPY 147.63B 22.57B 2025-03
Eli Lilly USD 10.5B 624.7M 2025-03
Exelixis USD 536.28M 10.51M 2025-04
Gilead Sciences USD 5.99B 17M 2024-12
GlaxoSmithKline GBP 5.59B 34M 2025-03
Grifols EUR 766.49M 39.74M 2024-12
Halozyme Therapeutics USD 216.46M 39.49M 2025-03
Incyte USD 985.09M 111.22M 2025-03
Ionis Pharmaceuticals USD 130.15M 92.6M 2025-03
Ironwood Pharmaceuticals USD 3.65M 60.36M 2024-09
MacroGenics USD 13.86M 94.98M 2024-12
Merck USD 12.77B 849M 2025-03
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
Novartis USD 10.23B 294M 2024-12
Pfizer USD 11.12B 987M 2025-03
Roche Holding CHF 11.69B 48M 2024-12
Sarepta Therapeutics USD 607.29M 81.18M 2025-03
Takeda JPY 671.32B 55.93B 2025-03
Teva Pharmaceutical Industries USD 1.91B 206M 2025-03
Xencor -45143000 40.69M 2024-09


Nektar Therapeutics Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Jul 2025.